Navigation Links
Industry And FDA Leaders To Discuss The Evolving Science Of Cardiovascular Safety (CV) And Diabetic Drug Development
Date:7/29/2009

The Drug Information Association (DIA) will host a two-day workshop on Cardiovascular Safety and Development of Type 2 Diabetes Mellitus Medications from September 23-24, 2009 in Washington, DC.

Horsham, PA, (PRWEB) July 29, 2009 -- The Drug Information Association (DIA) will host a two-day workshop on Cardiovascular Safety and Development of Type 2 Diabetes Mellitus Medications from September 23-24, 2009 in Washington, DC.

The workshop will examine evolving scientific data surrounding CV safety and diabetic drug development, future methods to make development of these drugs more streamlined while ensuring safety. Session topics will include:

 
  • Type 2 Diabetes: Clinical implications, CV manifestations, and epidemiology
  • Therapies and targets for treatment of Diabetes Mellitus - potential implications on CV safety
  • Glycemic control - evidence for positive and negative impacts on CV and renal outcomes in Type 2 DM
  • New trial design approaches to assessing CV safety
  • Clinical evidence that T2DM diabetic drugs can increase CV risk
  • Diabetic drug development and CV safety
  • Approaches to clinical analysis of CV risk
  • Novel clinical trial approaches
  • Future approaches to assessing T2DM drug development and CV safety
  • QT experience as a model for furthering collaborative approaches/research in CV

"Recent data published in major medical journals suggests possible increase in cardiovascular (CV) risk associated with the use of certain drugs for the treatment of type 2 diabetes (T2DM)," explains Program Chair Philip T. Sager, MD, FACC, Vice President, Clinical Research, Cardiopulmonary and Metabolic Clinical Development, Gilead Sciences, Inc. "As a result, the Division of Metabolism and Endocrinology Products of the US Food and Drug Administration (FDA) issued a new guidance in December 2008 recommending that all new T2DM drugs demonstrate CV safety in appropriately designed and powered outcome studies."

About the Drug Information Association (DIA):

DIA serves more than 30,000 professionals involved in the biopharmaceutical industry and regulatory affairs worldwide. Through its domestic and international meetings, training courses, workshops and webinars, DIA provides a neutral global forum for the exchange of information critical to the advancement of the drug discovery and lifecycle management processes. Headquartered in Horsham, PA, USA, and with offices in Basel, Switzerland, Tokyo, Japan, Mumbai, India, and Beijing, China, the Association is led by its volunteer-based Board of Directors and executive management team. For more information, visit www.diahome.org or call 215-442-6100.

Contact:

Joe Krasowski
Drug Information Association
215-293-5812
www.diahome.org

###

Read the full story at http://www.prweb.com/releases/dia/cv_diabetes_workshop/prweb2687594.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related medicine news :

1. EDI Health Group Continues to Drive Growth of EDI Processing Services in the Dental Healthcare Industry Through Addition of 25 New Connections in the First Half of 2009
2. Globaltel Media Appoints Leading Healthcare Industry Veterans to Advisory Board
3. Career Step Launches New Exam Prep Course for Medical Transcription Industry Credential
4. Nexicon Technology to Protect Healthcare Industry
5. Kirby Lesters New KL60: The Pharmacy Industrys First and Only Compact, Fully-Automated Dispensing System
6. Giant Bud Banner Half the Size of Football Field Flies Sunday Protesting Hydroponics Industry Cartel Monopoly that's Harming California's Medical Marijuana Patients
7. The Ensign Group Announces Appointment of Healthcare Industry Leader to Board of Directors
8. THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT Highlights the Burgeoning Demographics of Orthopaedics and the Continuing Health of the Industry
9. Claricode Launches Medical Software Scholarship Program with a Notable Judging Panel of Industry Experts
10. Career Step Partners with Computer Learning Center to Help Students Gain Careers in Growing Healthcare Industry
11. Michael J. Fox Foundation Awards $3.8 Million To Drive Nine Industry Partnerships For Pre-Clinical Parkinsons Drug Development
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Industry And FDA Leaders To Discuss The Evolving Science Of Cardiovascular Safety (CV) And Diabetic Drug Development 
(Date:4/28/2017)... Edinburg, Texas (PRWEB) , ... April 28, 2017 , ... ... a plaque in recently to the labor and delivery team at Women’s Hospital at ... generous mothers who give birth at the hospital and decide to donate. , ...
(Date:4/28/2017)... ... April 28, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh ... Creator responds to and which He does not. Yisrayl says with so many titles ... the true name, but he says with a little Scripture, backed with a lot of ...
(Date:4/28/2017)... ... 28, 2017 , ... NuevaCare, a leading home care agency based in San ... Alto, is proud to announce information upgrades to its blog in the form of ... on topics such as home care (generally) as well as senior care and home ...
(Date:4/27/2017)... ... 2017 , ... The Incentive Research Foundation is pleased to ... a groundbreaking analysis of how behavioral economics can be applied to the incentive, ... programs, the report highlights proven behavioral economics approaches and the powerful role emotions ...
(Date:4/27/2017)... ... April 27, 2017 , ... SyncDog, Inc. ... at MobileIron Live! 2017 in Santa Clara, California. Each year, MobileIron ... approach to helping organizations maximize the benefits of mobility in their operations securely. ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... NASHVILLE , Tenn. and DALLAS , ... and EndoStim, Inc., announced that the first patients in ... with the EndoStim device in the Lower Esophageal Sphincter ... is a minimally-invasive implantable device designed to provide long-term ... through neurostimulation. GERD affects nearly 65 million ...
(Date:4/19/2017)... , April 19, 2017  Novartis today announced ... National Heart, Lung, and Blood Institute (NHLBI) of ... 58% of patients with treatment-naïve severe aplastic anemia ... treated with eltrombopag at the initiation of and ... study evaluated three sequential treatment groups, or cohorts. ...
(Date:4/18/2017)... April 18, 2017 Research and Markets has ... report to their offering. ... The global arthroscopy devices market to grow at a CAGR of ... Arthroscopy Devices Market 2017-2021, has been prepared based on an in-depth ... market landscape and its growth prospects over the coming years. The ...
Breaking Medicine Technology: